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PRIMARY RESEARCH
Augmented expression of cardiac 
ankyrin repeat protein is induced 
by pemetrexed and a possible marker for the 
pemetrexed resistance in mesothelioma cells
Yiyang Qin1,2, Ikuo Sekine3, Mengmeng Fan4, Yuichi Takiguchi4, Yuji Tada5, Masato Shingyoji6, 
Michiko Hanazono1,5, Naoto Yamaguchi2 and Masatoshi Tagawa1,7*
Abstract 
Background: Pemetrexed (PEM) is an anti-cancer agent targeting DNA and RNA synthesis, and clinically in use for 
mesothelioma and non-small cell lung carcinoma. A mechanism of resistance to PEM is associated with elevated 
activities of several enzymes involved in nucleic acid metabolism.
Methods: We established two kinds of PEM-resistant mesothelioma cells which did not show any increase of the 
relevant enzyme activities. We screened genes enhanced in the PEM-resistant cells with a microarray analysis and 
confirmed the expression levels with Western blot analysis. A possible involvement of the candidates in the PEM-
resistance was examined with a WST assay after knocking down the expression with si-RNA. We also analyzed a 
mechanism of the up-regulated expression with agents influencing AMP-activated protein kinase (AMPK) and p53.
Results: We found that expression of cardiac ankyrin repeat protein (CARP) was elevated in the PEM-resistant cells 
with a microarray and Western blot analysis. Down-regulation of CARP expression with si-RNA did not however influ-
ence the PEM resistance. Parent and PEM-resistant cells treated with PEM increased expression of CARP, AMPK, p53 
and histone H2AX. The CARP up-regulation was however irrelevant to the p53 genotypes and not induced by an 
AMPK activator. Augmented p53 levels with nutlin-3a, an inhibitor for p53 degradation, and DNA damages were not 
always associated with the enhanced CARP expression.
Conclusions: These data collectively suggest that up-regulated CARP expression is a potential marker for develop-
ment of PEM-resistance in mesothelioma and that the PEM-mediated enhanced expression is not directly linked with 
immediate cellular responses to PEM.
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Background
Malignant mesothelioma, developed in the pleural cav-
ity, is highly resistant to a number of therapeutics and 
prognosis of the patients remains poor. A combination 
of pemetrexed (PEM) and cisplatin (CDDP) is the first-
line chemotherapy regimen for more than a decade [1]. 
No second-line regimen is yet established and molecular 
target agents did not produce better outcomes than the 
first-line agents [2]. Drug resistance to the anti-cancer 
agents, often developed in a number of the patients, is 
one of crucial issues in clinical settings and overcom-
ing the resistance is important in terms of the efficacy 
of chemotherapy. Machinery of CDDP resistance have 
been investigated in many types of cancer [3], but that an 
underlying mechanism to PEM resistance in mesotheli-
oma is unclear [4].
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Pemetrexed is a potent DNA and RNA synthesis inhibi-
tor and is reported to target three kinds of enzymes 
involved in purine and pyrimidine synthesis, thymidylate 
synthase (TS), dihydrofolate reductase (DHFR) and gly-
cinamide ribonucleotide formyltransferase (GARFT) [5]. 
An expression level of TS in tumors was linked to sensi-
tivity to PEM, but contribution of the other two enzymes 
to PEM-resistance remained unsettled [6]. Previous stud-
ies with lung cancer patients showed that PEM resistance 
was associated with an TS-linked enzyme such as ura-
cil-DNA glycosylase [7], and with expression of growth 
signal molecules including the epidermal growth factor 
receptor and p38 MAP kinase [8, 9]. PEM also inhibits 
an action of the aminoimidazolecarboxamide ribonucle-
otide formyltransferase, involved in a folate-mediated de 
novo purine synthesis, and consequently 5-amino-4-im-
idazolecarboxamide ribotide (ZMP) was accumulated in 
PEM-treated cells [10]. The intermediate molecules acti-
vates the AMP-activated protein kinase (AMPK) which 
influences a number of cell metabolism [11].
We previously established four kinds of PEM-resistant 
mesothelioma with a stepwise increase of PEM con-
centrations and assayed the resistance with a colony-
forming assay [12]. We found that all the resistant cells 
were not cross-resistant to CDDP and presumed a dif-
ferential mechanism as to drug resistance of the agents. 
We selected two kinds of PEM-resistant cells which did 
not increase expression of TS, DHFR or GARFT in com-
parison with the respective parent cells [12], and fur-
ther searched for a possible candidate which might be 
related with PEM resistance. In this study, we found with 
a microarray analysis that expression levels of six genes 
were elevated in two paired cells and investigated a pos-
sible role of the candidates in the PEM resistance. We 
identified one of the genes increased the expression and 
suggested it as a possible marker for PEM resistance.
Materials and methods
Cells and agents
Human mesothelioma cells, NCI-H28, NCI-H226, 
MSTO-211H and NCI-H2452, and immortalized Met-
5A cells of mesothelium origin were purchased from 
American Type Culture Collection (Manassas, VA, 
USA), and mesothelioma, EHMES-1 and JMN-1B 
cells, were provided by Dr. Hironobu Hamada (Hiro-
shima University, Japan) [13]. PEM-resistant H28-PEM, 
H226-PEM, 211H-PEM, and H2452-PEM cells were 
previously established by a stepwise increase of PEM 
(Eli Lilly, Indianapolis, IN, USA) [12]. Cells were cul-
tured with in RPMI-1640 medium supplemented with 
10% fetal calf serum, and confirmed to be negative for 
mycoplasma. The genotype of p53 was wild-type in NCI-
H28, NCI-H226, MSTO-211H and NCI-H2452 cells but 
p53 protein of NCI-H2452 cells was truncated [14]. In 
contrast, the genotype of EHMES-1 and JMN-1B cells 
was mutated. A769662 (Abcam, Cambridge, UK) and 
nutlin-3a (Selleck, Houston, TX, USA) were used to 
stimulate endogenous the AMPK and the p53 pathways, 
respectively.
Identification of genes up‑regulated in PEM‑resistant cells
An aliquot of total RNA was labeled with a fluorescence 
dye and hybridized with a whole human genome array 
(44Kx4 ver 2.0, Agilent Technologies, Santa Clare, CA, 
USA). Expression of respective genes and clustering 
of the gene expression was analyzed with GeneSpring 
GX11.5 (Agilent).
RNA interference
Cells were transfected with small interfering RNA (si-
RNA) duplex targeting cardiac ankyrin repeat protein 
(CARP) (si-RNA-s502326, s502327, s502328) (Thermo 
Fisher Scientific, Fremont, CA, USA), insulin-like growth 
factor binding protein-3 (IGFBP3) (si-RNA-s7227, s7228, 
s7229) (Thermo Fisher Scientific), or nonspecific si-
RNA as a control (Thermo Fisher Scientific) using Lipo-
fectamine RNAiMAX according to the manufacturer’s 
protocol (Thermo Fisher Scientific).
Reverse transcription‑polymerase chain reaction (RT‑PCR)
Total RNAs were isolated with TRIzol reagent (Thermo 
Fisher Scientific) from cells transfected with siRNAs for 
IGFBP3. First-strand cDNA was synthesized from the 
RNA preparations using Superscript III reverse tran-
scriptase (Invitrogen, Carlsbad, CA, USA) and amplifica-
tion of equal amounts of the cDNA was performed with 
the following primers and conditions: for the IGFBP3 
gene, 5′-GACAGAATATGGTCCCTGCCG-3′ (forward) 
and 5′-TTGGAAGGGCGACACTGCT-3′ (reverse), and 
15 s at 95 °C for denature/45 s at 60 °C for annealing/26 
cycles; for the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene, 5′-ACCACAGTCCATGCCATCAC-3′ 
(forward) and 5′-TCCACCACCCTGTTGCTGTA-3′ 
(reverse), and 15 s at 94 °C/15 s at 60 °C/25 cycles.
Cell viability test
Cells were seeded into 96-well plates (2.8  ×  103 cells 
per well), treated with si-RNA or human recombinant 
IGFBP3 (Wako, Osaka, Japan) for 24  h and then incu-
bated with PEM for 72  h. Cell viabilities were assessed 
with a WST-8 kit (Dojindo, Kumamoto, Japan) and the 
relative viability was calculated based on the absorbance 
at 450 nm without any treatments (WST assay). Graph-
Pad Grism ver 6.0 (GraphPad Grism Software, San Diego, 
CA, USA) was used to calculate 50 or 75% inhibitory 
concentrations  (IC50 and  IC75).
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Western blot analysis
Cell lysate was subjected to sodium dodecyl sulfate–pol-
yacrylamide gel electrophoresis. The protein was trans-
ferred to a nitrocellulose membrane and was hybridized 
with antibody against integrin β-3 (Catalog Number: 
#13166), AMPK (#2532), phosphorylated AMPK (Thr 
172) (#2535), phosphorylated p53 (Ser 15) (#9284) (Cell 
Signaling, Danvers, MA, USA), plasminogen activa-
tor inhibitor (#ab20562), a disintegrin and metallo-
proteinase with thrombospondin motifs 5 (#ab41037) 
(Abcam), IGFBP3 (#sc-9028), CARP (sc-30181), β-2 adr-
energic receptor (#sc-569) (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), phosphorylated H2AX (Ser 139) 
(#613401) (BioLegend, San Diego, CA, USA), p53 (Ab-
6, Clone DO-1) and tubulin-α (Clone DM1A) (Thermo 
Fisher Scientific) as a control followed by an appropriate 
second antibody. The membranes were developed with 
the ECL system (GE Healthcare, Buckinghamshire, UK).
Enzyme‑linked immunosorbent assay (ELISA) for IGFBP3
IGFBP3 concentrations in culture supernatants and cell 
lysate were measured with a human IGFBP3 ELISA kit 
(R&D Systems, Minneapolis, USA) according to the manu-
facturer’s instructions. Optical density was measured based 
on the absorbance at 450 nm using a micro-plate reader.
Results
PEM‑resistance assayed with the WST assay
We established PEM-resistant cells, H28-PEM, H226-
PEM, 211H-PEM and H2452-PEM, from respective 
parent cells, NCI-H28, NCI-H226, MSTO-211H and 
NCI-H2452, and showed the resistance with a colony-
forming assay [12]. We then demonstrated the resistance 
with the WST assay by measuring relative cell viability 
after an exposure to various PEM concentrations (Fig. 1). 
We confirmed that all kinds of the PEM-resistant cells 
were less sensitive to PEM than their parent cells. NCI-
H28, NCI-H229 and MSTO-211H cells showed simi-
lar PEM sensitivity but NCI-H2452 cells were relatively 
resistant to PEM.
Identification of up‑regulated genes in PEM‑resistant cells
We previously showed that both 211H-PEM and 
H2452-PEM cells elevated TS and GARFT mRNA 
0
25
50
75
100
0 0.01 0.03 0.1 0.3 1 3 10 30
MSTO-211H
MSTO-211H
211H-PEM
Pemetrexed (μg/ml)
0
25
50
75
100
0 0.01 0.03 0.1 0.3 1 3 10 30
NCI-H2452
NCI-H2452
H2452-PEM
0
25
50
75
100
0 0.01 0.03 0.1 0.3 1 3 10 30
NCI-H226
NCI-H226
H226-PEM
0
25
50
75
100
0 0.01 0.03 0.1 0.3 1 3 10 30
NCI-H28
NCI-H28
H28-PEM
)
%(
ytilibaiv
evitale
R
(IC50=0.030)
(IC50=0.19)
(IC50=0.072)
(IC50>30)
(IC50=0.064)
(IC50>30) (IC75=0.072)
(IC75>30)
Fig. 1 Sensitivity of parent and PEM-resistant cells to PEM. Paired cells of parent and PEM-resistant cells, NCI-H28 and H28-PEM, NCI-H226 and 
H226-PEM, MSTO-211H and 211H-PEM, and NCI-H2452 and H2452-PEM cells, were treated with various concentrations of PEM for 72 h. Cell viability 
was measured with the WST assay. Representative data with averages and SE bars (n = 3), and  IC50 (NCI-H28, NCI-H226, MSTO-211H cells and the 
respective PEM-resistant cells) and  IC75 (NCI-H2452 and H2452-PEM cells) values are shown
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expression in comparison with respective parent cells, 
whereas the expression levels of H28-PEM and H226-
PEM cells were not elevated or rather lower than those 
of their parent cells [12]. The DHFR transcripts in H28-
PEM and H226-PEM cells also decreased compared 
with the parent cells [12]. We thereby selected two kinds 
of paired cells, NCI-H28 and H28-PEM, and NCI-H226 
and H226-PEM cells, for further analyses to select the 
genes which elevated the expression greater in PEM-
resistant than in the parent cells. We first conducted a 
microarray analysis which compared gene expression 
profiles of parent cells with that of PEM-resistant cells 
in the four kinds of mesothelioma cells (Additional 
file  1: Fig. S1). We included CDDP-resistant mesothe-
lioma cells in the analyses, which were also established 
with the same method as the PEM-resistant cells [12]. 
The analysis detected 21,964-24,509 spots in these par-
ent cells and similar spot numbers were also found in 
respective CDDP- and PEM-resistant cells. A hierarchi-
cal clustering analysis with 19,307 spots revealed that 
differential expression profiles of respective parent cells 
were distinctive among these parent cells more than 
those between individual parent cells and the respective 
CDDP- or PEM-resistant cells. We therefore screened 
genes of which the expression were up-regulated in 
PEM-resistant cells 5 times greater than that in the par-
ent cells, and identified six genes from the two kinds 
paired cells (Table 1).
CARP and IGFBP3 were differentially expressed 
in PEM‑resistant cells
We examined expression levels of the six up-regulated 
genes in four paired cells with Western blot analysis 
(Fig. 2). The analysis showed that CARP expression was 
augmented in PEM-resistant cells except H2452-PEM 
cells. IGFBP3 expression showed multiple bands and the 
intensity in total seemed to increase in all the 4 PEM-
resistant cells. The band of the highest molecular weight 
(50 kDa) however turned out to be a non-specific signal 
based on experiments with the si-RNA for IGFBP3 and 
ELISA (see below). The rest of IGFBP3 bands repre-
sented several isoforms migrated at molecular weights 
between 40 and 44  kDa. The IGFBP3 expression in 
H226-PEM cells could be greater than that in NCI-H226 
cells, whereas the expression in H28-PEM cells, showing 
only a non-specific band at 50 kDa, rather decreased in 
comparison with that in the parent cells expressing the 
multiple isoforms. The IGFBP3 level in 211H-PEM and 
H2452-PEM cells was marginally greater than that of the 
respective parent cells. In contrast, expression of other 
molecules, PAI1, ADRB2, ADAMTS5 and ITGB3, was 
not different between the PEM-resistant and the par-
ent cells. We selected CARP and IGFBP3 based on the 
Table 1 Genes up-regulated in the expression 5 times greater in PEM-resistant cells then in the parent cells
Candidate genes listed were confirmed for the differential mRNA expression levels both in paired cells
Gene Ratio of the expression (PEM‑resistant cells/parent 
cells)
H28‑PEM/NCI‑H28 H226‑PEM/NCI‑H226
Cardiac ankyrin repeat protein (CARP) 6.320 28.949
Adrenergic receptor β-2 (ADRB2) 8.997 21.626
Plasminogen activator inhibitor 1 (PAI1) 9.017 10.212
Integrin β-3 (ITGB3) 10.944 9.041
A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) 7.787 7.233
Insulin-like growth factor binding protein-3 (IGFBP3) 10.861 5.174
CARP
IGFBP3
PAI1
ADRB2
ADAMTS5
ITGB3
Tubulin-α
parent PEM parent PEM parent PEM parent PEM
40 kDa
50 kDa
40-44 kDa
45 kDa
56 kDa
75 kDa
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Fig. 2 CARP and IGFBP3 were differentially expressed in PEM-resist-
ant cells. Expression of six candidate molecules in parent and PEM-
resistant cells (PEM) were examined with Western blot analysis. Cell 
lysates were probed with antibody as indicated. Tubulin-α was used 
as a loading control. Dotted arrow indicates a non-specific signal and 
arrows shows authentic IGFBP3 signals
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differential expression levels and further examined the 
functions in PEM-resistance. We currently do not know a 
reason of the discrepant levels between mRNA and pro-
tein in respective paired cells.
Decreased CARP expression did not influence the 
PEM‑resistance
We examined a possible role of CARP in the PEM resist-
ance by down-regulating the expression with si-RNA. 
We firstly investigated transfection efficiency with differ-
ent doses of Alexa Fluor red fluorescent control in H28-
PEM cells (Additional file 2: Table S1). The fluorescence 
values showed that 10 nM si-RNA was enough to obtain 
sufficient efficacy. H28-PEM cells were then treated with 
three kinds of si-RNA for CARP (s502326, s502327 and 
s502328) and each kind of si-RNA down-regulated the 
CARP expression (Fig. 3a). The cells, irrespective of the 
si-RNA, did not show any changes in their sensitivity to 
PEM (Fig. 3b). We also tested 221H-PEM cells, express-
ing CARP greater than parent MSTO-211H cells, and 
found that the si-RNA treatments did not enhance the 
PEM sensitivity (Additional file 3: Fig. S2). These results 
suggested that elevated CARP expression did not con-
tribute to the PEM resistance.
Production of IGFBP3 was not correlated with the PEM 
resistance
We measured the production of IGFPB3 in culture 
supernatants and cell lysate with an ELISA kit (Table 2). 
H226-PEM cells produced IGFBP3 greater than the 
parent cells in culture supernatants and cell lysate, but 
H28-PEM cells rather produced less amounts of IGFBP3 
compared with the parent cells. These ELISA data were 
concordant with the expression levels detected with 
Western blot analysis. We further examined a possible 
role of IGFBP3 in the drug resistance since IGFBP3 influ-
enced IGF-mediated signaling which was linked with 
the drug insensitivity [15]. We transfected three kinds 
of si-RNA for IGFBP3 (s7227, s7228, and s7229) into 
H226-PEM cells and examined the expression levels with 
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Fig. 3 Effects of decreased CARP expression on PEM-resistance. a H28-PEM cells were transfected with si-RNA for CARP (three kinds, s502326, 
s502327 and s502328) at different concentrations and CARP expression levels were examined with Western blot analysis 48 h after the transfection. 
Tubulin-α was used as a loading control. b Cell viability of H28-PEM cells transfected with si-RNA for CARP (10 nM) or control si-RNA (10 nM) and 
then treated with PEM for 72 h. The cell viability was measured with the WST assay. SE bars are shown (n = 3)
Table 2 Production of IGFBP3 from mesothelioma cells
IGFBP3 amounts from supernatants of 2 days-culture or cell lysate were 
measured with ELISA
The amounts were calculated with a standard IGFBP3 protein and SEs are also 
shown (n = 3)
Source Cells Amounts (ng per 1 × 106 cells)
(Average ± SE)
Supernatants NCI-H28 24.01 ± 0.09
H28-PEM 6.31 ± 0.03
NCI-H226 100.57 ± 0.18
H226-PEM 131.10 ± 0.61
Cell lysate NCI-H28 3.01 ± 0.02
H28-PEM 1.35 ± 0.01
NCI-H226 9.56 ± 0.13
H226-PEM 23.26 ± 0.37
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their parent cells with ELISA (Additional file 4: Fig. S3) 
and Western blot analysis (Fig.  4a). ELISA data showed 
decreased production of IGFBP3 and Western blot data 
indicated that the band corresponding the highest molec-
ular weight remained unchanged in the intensity, but 
lower bands below the highest became significantly weak. 
We also examined various doses of si-RNA and con-
firmed down-regulated IGFBP3 transcripts (Fig. 4b). The 
si-RNA treatments showed that intensity of the lower 
bands decreased in a dose-dependent manner (Fig.  4c). 
These si-RNA experiments confirmed that the lower 
molecular bands but not the highest band corresponded 
to IGFBP3. We then tested the PEM sensitivity of H226-
PEM cells treated with the si-RNA and showed that 
knocking down of IGFBP3 did not improve susceptibil-
ity to PEM (Fig. 4d). We also examined whether recom-
binant IGFBP3 decreased PEM sensitivity to NCI-H226 
cells but the exogenous IGFBP3 did not affect the sensi-
tivity in a dose-dependent manner (Additional file 5: Fig. 
S4). These data collectively showed that IGFBP3 was not 
involved in susceptibility to PEM. 
PEM induced up‑regulated CARP but not IGFBP3 
expression
We examined possible augmentation of CARP and 
IGFBP3 expression with PEM treatments. We treated 
paired cells with PEM and investigated the expression 
with Western blot analysis (Fig.  5). Both NCI-H28 and 
H28-PEM cells augmented CARP expression, but up-
regulation of the IGFBP3 was minimal. NCI-H226 cells 
and less significantly H226-PEM cells showed increased 
CARP expression with PEM treatments, but the IGFBP3 
expression was minimally or scarcely changed. These 
data therefore showed that PEM treatments up-regulated 
CARP but not IGFBP3 expression.
Augmented p53 contributed to the CARP up‑regulation
We investigated a mechanism of the constitutive increase 
of CARP expression by treating cells with PEM (Fig. 5). 
We firstly examined p53 expression after PEM treat-
ments in NCI-H28 and NCI-H226 cells, both of which 
had the wild-type p53 genotype, and in the PEM-resist-
ant cells. The PEM treatments induced phosphorylation 
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Fig. 4 Effects of decreased IGFBP3 expression on PEM-resistance. a–c si-RNA for IGFBP3 (20 nM) (s7227, s7228 and s7229) or different amounts of 
si-RNA for IGFBP3 (3, 10 and 20 nM), and control si-RNA (si-Cont) were transfected into H226-PEM cells, and suppression of IGFBP3 expression was 
confirmed by RT-PCR (b) and Western blot analysis (a, c) 48 h after the transfection. Tubulin-α was used as a loading control. Dotted arrow indicates 
a non-specific signal and arrows shows authentic IGFBP3 signals. d Cell viability of H226-PEN cells transfected with si-RNA for IGFBP3 (3 nM) or 
control si-RNA (3 nM) and then treated with PEM for 72 h. The cell viability was measured with the WST assay. SE bars are shown (n = 3)
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of p53 at serine 15 in NCI-H28, H28-PEM and NCI-
226H cells, and consequently the p53 levels were up-
regulated in these cells. In contrast, H228-PEM cells did 
not show the augmented p53 expression or phosphoryl-
ated p53, which could be attributable to less sensitivity of 
the cells to PME-mediated cytotoxicity. We then exam-
ined induction of phosphorylated H2AX, a DNA damage 
marker, and found that the enhanced level in H228-PEM 
cells was less than that in the other cells which showed 
the increased expression in a time- and a dose-depend-
ent manner. These data suggested that the up-regulated 
level of CARP was associated with a degree of DNA 
damages followed by activation of the p53 pathways. We 
therefore examined whether the CARP up-regulation 
was linked with the p53 genotype. We used mesothe-
lioma cells with mutated p53 genotype, EHMES-1 and 
Phospho-H2AX
Tubulin-α
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p53
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AMPK
Phospho-AMPK
NCI-H28
Pemetrexed (μg/ml)
CARP
( ) 0.1
24 48 
0.3
24 48 
H28-PEM
( ) 0.1
24 48 
0.3
24 48 (hrs)
NCI-H226
( ) 0.1
24 48
0.3
24 48 
H226-PEM
( ) 0.1
24 48 
0.3
24 48
Tubulin-α
IGFBP3
Pemetrexed (μg/ml)
CARP
p53
Phospho-p53
AMPK
Phosepho-AMPK
Phospho-H2AX
(hrs)
a
b
40 kDa
50 kDa
40-44 kDa
53 kDa
53 kDa
14 kDa
62 kDa
62 kDa
57 kDa
40 kDa
50 kDa
40-44 kDa
53 kDa
53 kDa
14 kDa
62 kDa
62 kDa
57 kDa
Fig. 5 PEM induced differential molecular expression in parent and PEM-resistant cells. Parental and PEM-resistant cells, a NCI-H28 and H28-PEM 
and b NCI-H226 and H226-PEM, were treated with PEM (0.1 or 0.3 μg/ml) for 24 or 48 h and the cell lysates were probed with respective kinds of 
antibody. Exposure times between (a) and (b) blots were not equal. Tubulin-α was used as a loading control. Dotted arrow indicates a non-specific 
signal and arrows shows authentic IGFBP3 signals
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JMN-1B, and mesothelium-derived immortalized Met-
5A cells that expressed the SV40 T antigen (Fig. 6). PEM-
treated EHMES-1 cells augmented CARP expression 
levels, but JMN-1B cell and more remarkably Met-5A 
cells decreased the expression, whereas phosphorylated 
H2AX levels increased in all the cells upon PEM treat-
ments. These data thereby indicated that PEM-mediated 
CARP augmentation was not directly dependent on 
DNA damages. We further examined whether augmenta-
tion of endogenous p53 without DNA damages contrib-
uted to increased CARP expression. Nutlin-3a inhibited 
interaction between p53 and MDM2 molecules which 
mediated ubiquitination of p53 and subsequent p53 deg-
radation [16]. Nutlin-3a-treated cells with the wild-type 
p53 therefore increased p53 levels due to inhibiting the 
p53 degradation processes (Fig.  7). NCI-H28 and H28-
PEM cells treated with nutlin-3a increased CARP expres-
sion levels, whereas treated NCI-H226 and H226-PEM 
cells rather decreased the CARP levels except a tempo-
rally increased NCI-H226 sample treated at 20  μM for 
48 h. Phosphorylated levels of H2AX were dependent on 
a cell type and a treated dose. Cells originated from NCI-
H28 cells increased endogenous p53 without increased 
H2AX phosphorylation but those from NCI-H226 cells 
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24
0.1 0.3
48 
0.1 0.3
Tubulin-α
Pemetrexed (μg/ml)
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Fig. 6 CARP expression in PEM-treated cells mesothelioma with mutated p53 genotype or immortalized mesothelial cells expressing dominant-
negative p53. Cells were in treated with PEM (0.1 or 0.3 μg/ml) for 24 or 48 h. Cell lysates were probed with antibody as indicated. Tubulin-α was 
used as a loading control
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Fig. 7 CARP expression in nutlin-3a-treated cells. Parent and the PEM-resistant cells were treated with nutlin-3a or DMSO as a solvent for 24 or 48 h 
and the cell lysate was probed with antibody as indicated. Tubulin-α was used as a loading control
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augmented the phosphorylation at 50  μM nutlin-3a 
treatments. Nutlin-3a was not essentially genotoxic but 
treatments at a high concentration induced DNA dam-
ages in cells of NCI-H226 origin. These data collectively 
indicated that a way of CARP induction was subjected 
to cell type difference. Activation of the p53 pathways in 
NCI-H28 cells was associated with the increased CARP 
expression but DNA damages was irrelevant. In contrast, 
neither p53 up-regulation nor DNA damages were linked 
in cells derived from NCI-H226 cells.
We also examined the effects of PEM on AMPK 
expression and the phosphorylation (Fig. 5). All the cells 
including H226-PEM cells increased phosphorylation of 
AMPK but the AMPK levels remained unchanged, which 
indicated that PEM stimulated the AMPK signal path-
way. These data raised possibility that PEM-mediated 
augmentation of CARP expression was attributable to 
activation of the AMPK pathway. We then examined a 
role of the AMPK activation with an AMPK stimulating 
agent, A769662 (Fig.  8). NCI-H28 and NCI-H226 cells 
treated with A769662 increased phosphorylated AMPK, 
but the CARP expression was not induced or rather 
decreased. IGFBP3 was not induced by A769662 either. 
These data showed that activation of AMPK pathway was 
not involved in the PEM-mediated CARP augmentation.
Discussion
We showed up-regulated CARP expression in PEM-
resistant mesothelioma cells and demonstrated that PEM 
treatments augmented the CARP expression. The PEM 
treatments induced DNA damages, up-regulated p53 
expression and phosphorylation of AMPK, but the cur-
rent study indicated that the CARP augmentation was 
irrelevant to DNA damages or AMPK activation, but was 
associated with activation of the p53 pathways in some 
of cells with the wild-type p53 genotype. Furthermore, 
we demonstrated that down-regulation of CARP did not 
influence on PEM sensitivity.
Expression of CARP in human tumors has not well 
investigated. A previous report showed that clinical 
specimens of rhabdomyosarcoma expressed the protein 
at a high frequency since the tumors were derived from 
CARP-positive striated muscles [17]. In contrast, non-
rhabdomyosarcoma expressed CARP at a low frequency 
[17] and the expression in mesothelioma has not been 
investigated. CARP physiologically functions not only 
as a structural component of muscle sarcomere but as 
a transcriptional co-factor mediating gene expression 
for muscle stretches [18]. Moreover, the expression in 
endothelial cells can be linked with wound healing and 
neovascularization, which may be regulated at the tran-
scriptional level [19]. Regulation of the expression and the 
functions in non-muscular tissues and tumors can also 
be distinctive from muscular tissues. A possible relation 
between CARP expression and drug resistance remained 
unknown except ovarian cancer [20, 21]. CDDP-resistant 
ovarian carcinoma cells expressed CARP at a high level 
and CDDP treatments decreased the CARP expression. 
Furthermore down-regulation of CARP with the si-RNA 
increased susceptibility to CDDP [20, 21]. These previous 
studies collectively suggested that CARP worked for cell 
survival. In contrast, the present data showed that CARP 
expression increased upon PEM treatments, but down-
regulated CARP was irrelevant to the PEM sensitivity 
although the CARP expression was up-regulated in PEM-
resistant cells. A possible role of CARP in drug resistance 
can be different among tumors and dependent on chem-
otherapeutic agents.
The current study showed that PEM treatments 
increased not only CARP expression but p53, the phos-
phorylated p53, phosphorylated H2AX and phosphoryl-
ated AMPK levels. PEM is a DNA damaging agent and 
both NCI-H28 and NCI-H226 cells had the wild-type 
p53 gene; consequently, PEM stimulated the p53 path-
ways through a DNA damaging signal. We then exam-
ined a possible role of the p53 pathways in augmentation 
of CARP expression. EHMES-1 cells mutated p53 geno-
type increased CARP expression, whereas the expression 
of JMN-1B cells with the mutated genotype remained 
unchanged. Furthermore, immortalized Met-5A cells 
with loss of p53 functions decreased the expression. 
These data collectively indicate that enhanced expression 
of CARP was not always associated with activation of the 
p53 pathways. On the other hand, PEM induced DNA 
damages, evidenced by phosphorylated H2AX expres-
sion, in all the cells. We therefore examined the CARP 
expression with nutlin-3a, which induced p53 under a 
non-genotoxic condition, and found that CARP expres-
sion was enhanced in NCI-H28 and the PEM-resistant 
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Tubulin-α
Phospho-AMPK
AMPK
A769662 (μM)
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IGFBP3
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Fig. 8 CARP expression in cells treated with an AMPK activating 
agent. NCI-H28 and NCI-H226 cells were treated with A769662 at vari-
ous concentrations as indicated for 48 h. The cell lysates were probed 
with respective antibody. Tubulin-α was used as a loading control
Page 10 of 11Qin et al. Cancer Cell Int  (2017) 17:120 
cells. Nutlin-3a at a high concentration however induced 
DNA damages in NCI-H226 and the PEN-resistant 
cells probably due to off-target effects. Nevertheless, 
the cells treated with a low concentration of nutlin-3a 
augmented p53 levels without DNA damages. CARP 
expression levels in NCI-H226 and the PEM-resistant 
cells remained unchanged in most of the cases irrespec-
tive of p53 up-regulation and DNA damages. These data 
indicated that the CARP up-regulation was linked with 
activation of the p53 pathways but not with DNA dam-
ages in some of mesothelioma cells. Interestingly, a pre-
vious study showed that CARP induced p53 expression 
and p53 in turn activated CARP transcription [22]. The 
present study did not fully support the reciprocal induc-
tion between CARP and p53 since nutlin-3a differen-
tially influenced on CARP expression in NCI-H28 and 
NCI-H226 cells. The present study rather indicated that 
p53-induced CARP up-regulation was dependent on cell 
types. Expression of CARP is also regulated by a num-
ber of factors including GADD153 and SMAD4 [19, 23]. 
These regulatory factors are further influenced by various 
conditions and their expression are controlled by differ-
ent mechanisms. GADD153 is in fact induced by DNA 
damages and down-regulated CARP [23]. The cell type 
difference of CARP induction can therefore be attribut-
able to complexity of the gene regulations.
Pemetrexed also stimulated the AMPK pathway that 
was evidenced by phosphorylated AMPK. PEM-treated 
cells accumulated ZMP, an intermediated AMP analogue, 
activated the APMK [10, 11]. We used an AMPK activat-
ing agent, A769662, to examine a possible involvement 
of AMPK activation but the AMPK agonist did not aug-
ment CARP expression. The current study consequently 
showed that AMPK activation was not involved in up-
regulation of CARP expression.
We established PEM-resistant cells but a possible 
mechanism of the drug insensitivity was not well char-
acterized. Comparison of parent and the PEM-resistant 
cells after PEM treatments revealed less DNA damages 
induced in H226-PEM cells than NCI-H226 cells. Phos-
phorylation of p53 was also insignificant in PEM-treated 
H226-PEM cells, whereas nutlin-3a-treated H226-PEM 
cells augmented p53 and phosphorylated H2AX to a 
similar degree as the parent cells. These data indicated 
that one of the mechanisms for PEM resistance in H226-
PEM cells was linked with an impaired system of sens-
ing PEM-mediated DNA damages. Our previous study 
showed that acquired PEM insensitivity was irrelevant to 
several enzyme activities which mediated PEM metabo-
lism and the current investigation implied possible corre-
lation between the resistance and CARP up-regulation. A 
precise mechanism of the augmented CARP expression 
remains yet unclear and the increased expression was not 
related with PEM resistance. A continuous stimulation 
of the AMPK system by PEM may result in suppression 
of the mammalian target of rapamycin pathway, one of 
the targets of AMPK, and subsequently decrease DNA 
synthesis, which can be linked with PEM resistance. 
We therefore speculate that constitutive AMPK activa-
tion contributes to PEM insensitivity and presume that 
investigation on this association will be one of the next 
research targets.
Mesothelioma often develops into being resistant to 
the first-line agent after a few courses of chemotherapy 
and no second-line regimen is yet known. A biomarker 
for the PEM-resistance is therefore not clinically useful at 
this moment and moreover clinical specimens from the 
patients who fail to respond are usually unavailable. Nev-
ertheless, early detection of PEM-resistance, although 
such a marker not currently known, will be beneficial for 
the patients to evaluate their current therapeutics and be 
valuable when shifting into a possible second-line agent 
that is hopefully available in future.
Conclusions
We demonstrated that CARP expression was elevated in 
PEM-resistant mesothelioma cells and suggested that the 
up-regulated expression was a candidate marker for PEM 
resistance in mesothelioma although down-regulated 
CARP expression did not influence the PEM sensitivity. 
The augmented CARP expression was not always linked 
with immediate cellular responses but activation of the 
p53 pathways, depending on cell types, was involved in 
the CARP up-regulation.
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with si-RNA for CARP (10 nM) or control si-RNA (10 nM) and then treated 
with PEM for 72 hrs. The cell viability was measured with the WST assay. SE 
bars are shown (n=3).
Additional file 4: Figure S3. Inhibited secretion of IGFBP3 with si-RNA. 
H226-PEM cells were transfected with si-RNA for IGFBP3 (20 nM) (s7227, 
s7228 and s7229) or control si-RNA (si-Cont), and the culture supernatants 
were assayed with ELISA. We measured optical density at 450 nm and 
used 10 ng rhIGFBP3 as a positive control. Average and SE bars are shown 
(n=3).
Additional file 5: Figure S4. Influence of recombinant human IGFBP3 
(rhIGFBP3) on PEM-resistance. NCI-H226 cells were treated with different 
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PEM for further 72 hrs. Cell viability was measured using the WST assay. SE 
bars are shown (n=3).
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